PL3333173T3 - Sposoby wytwarzania przeciwwirusowych analogów nukleotydów - Google Patents
Sposoby wytwarzania przeciwwirusowych analogów nukleotydówInfo
- Publication number
- PL3333173T3 PL3333173T3 PL18153951T PL18153951T PL3333173T3 PL 3333173 T3 PL3333173 T3 PL 3333173T3 PL 18153951 T PL18153951 T PL 18153951T PL 18153951 T PL18153951 T PL 18153951T PL 3333173 T3 PL3333173 T3 PL 3333173T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- nucleotide analogs
- preparing anti
- viral nucleotide
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12798029.0A EP2764002B1 (en) | 2012-10-03 | 2012-10-03 | Methods for preparing anti-viral nucleotide analogs |
| EP18153951.1A EP3333173B1 (en) | 2012-10-03 | 2012-10-03 | Methods for preparing anti-viral nucleotide analogs |
| PCT/US2012/000441 WO2013052094A2 (en) | 2011-10-07 | 2012-10-03 | Methods for preparing anti-viral nucleotide analogs |
| US201161544950P | 2014-04-11 | 2014-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3333173T3 true PL3333173T3 (pl) | 2019-12-31 |
Family
ID=47297386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18153951T PL3333173T3 (pl) | 2012-10-03 | 2012-10-03 | Sposoby wytwarzania przeciwwirusowych analogów nukleotydów |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US8664386B2 (pl) |
| EP (2) | EP3333173B1 (pl) |
| JP (2) | JP6190372B2 (pl) |
| KR (3) | KR102033802B1 (pl) |
| CN (4) | CN107266498B (pl) |
| AR (1) | AR088109A1 (pl) |
| AU (3) | AU2012319172B2 (pl) |
| BR (2) | BR112014011340A2 (pl) |
| CA (2) | CA3042169C (pl) |
| CL (1) | CL2014000827A1 (pl) |
| CO (1) | CO6940431A2 (pl) |
| CR (1) | CR20140204A (pl) |
| EA (1) | EA027086B1 (pl) |
| EC (1) | ECSP14000074A (pl) |
| ES (2) | ES2746859T3 (pl) |
| HK (1) | HK1255222B (pl) |
| IL (1) | IL231879B (pl) |
| MX (1) | MX353064B (pl) |
| PE (1) | PE20141160A1 (pl) |
| PL (1) | PL3333173T3 (pl) |
| PT (2) | PT3333173T (pl) |
| SI (1) | SI3333173T1 (pl) |
| TW (4) | TWI709567B (pl) |
| UY (1) | UY34361A (pl) |
| WO (1) | WO2013052094A2 (pl) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| CN107266498B (zh) * | 2011-10-07 | 2023-10-03 | 吉利德科学公司 | 制备抗病毒核苷酸类似物的方法 |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| EP3004121A1 (en) * | 2013-06-07 | 2016-04-13 | Cipla Limited | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine |
| CN104628773B (zh) * | 2013-11-06 | 2018-10-23 | 杭州和泽医药科技有限公司 | (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法 |
| IN2013CH05455A (pl) * | 2013-11-27 | 2015-08-07 | Laurus Labs Private Ltd | |
| WO2015107451A2 (en) * | 2014-01-14 | 2015-07-23 | Mylan Laboratories Ltd. | Purification of tenofovir alafenamide and its intermediates |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| CN105518011B (zh) * | 2014-04-21 | 2018-07-27 | 四川海思科制药有限公司 | 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法 |
| WO2015197006A1 (zh) * | 2014-06-25 | 2015-12-30 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
| CN105399771B (zh) * | 2014-07-21 | 2020-11-24 | 江苏豪森药业集团有限公司 | 替诺福韦前药晶型及其制备方法和用途 |
| CN108148094A (zh) * | 2014-11-12 | 2018-06-12 | 四川海思科制药有限公司 | 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途 |
| CN104817593B (zh) * | 2015-04-27 | 2016-11-16 | 广州同隽医药科技有限公司 | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 |
| AU2016302009B2 (en) | 2015-08-05 | 2021-09-30 | Eisai R&D Management Co., Ltd. | Chiral reagents for preparation of homogeneous oligomers |
| TWI616452B (zh) * | 2015-08-26 | 2018-03-01 | Preparation method of nucleoside analog and intermediate thereof | |
| CN105330700A (zh) * | 2015-12-17 | 2016-02-17 | 中国药科大学 | 富马酸替诺福韦艾拉酚胺杂质的制备方法 |
| WO2017118928A1 (en) | 2016-01-06 | 2017-07-13 | Lupin Limited | Process for the separation of diastereomers of tenofovir alafenamide |
| CZ2016156A3 (cs) * | 2016-03-17 | 2017-09-27 | Zentiva, K.S. | Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí |
| CN107286190A (zh) * | 2016-04-13 | 2017-10-24 | 刘沛 | 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN106565785B (zh) * | 2016-11-09 | 2019-11-12 | 周雨恬 | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 |
| CN106946935B (zh) * | 2017-04-28 | 2020-01-07 | 福建广生堂药业股份有限公司 | 一种非对映异构体核苷衍生物的制备方法 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN111417634A (zh) * | 2017-10-04 | 2020-07-14 | 细胞基因公司 | 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法 |
| CN109942633B (zh) * | 2017-12-20 | 2021-08-31 | 上海新礼泰药业有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN109942632B (zh) * | 2017-12-20 | 2021-08-31 | 上海博志研新药物研究有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN110092803A (zh) * | 2018-01-31 | 2019-08-06 | 北京睿创康泰医药研究院有限公司 | 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用 |
| CN108409788B (zh) * | 2018-03-12 | 2020-05-08 | 科兴生物制药股份有限公司 | 一种富马酸替诺福韦艾拉酚胺的制备方法 |
| CN110305163A (zh) * | 2018-03-27 | 2019-10-08 | 北京济美堂医药研究有限公司 | 替诺福韦艾拉酚胺半富马酸盐的制备方法 |
| CN108467410B (zh) * | 2018-04-09 | 2021-04-09 | 重庆三圣实业股份有限公司 | 一种taf中间体的制备方法及产品和应用 |
| CN108484672A (zh) * | 2018-05-23 | 2018-09-04 | 中国药科大学制药有限公司 | 磷丙替诺福韦的手性拆分方法 |
| CN108822149B (zh) * | 2018-06-01 | 2020-08-11 | 成都苑东生物制药股份有限公司 | 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法 |
| CN110283208B (zh) * | 2018-06-22 | 2022-07-08 | 南京济群医药科技股份有限公司 | 一种替诺福韦艾拉酚胺的手性拆分方法 |
| CN109081853A (zh) * | 2018-09-03 | 2018-12-25 | 南京正大天晴制药有限公司 | 一种磷丙替诺福韦有关物质的制备方法 |
| CN111484527A (zh) * | 2019-01-25 | 2020-08-04 | 上海清松制药有限公司 | 一种替诺福韦艾拉酚胺中间体的制备方法 |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| CN111943981A (zh) * | 2019-05-14 | 2020-11-17 | 博瑞生物医药泰兴市有限公司 | 一种磷丙替诺福韦的制备方法 |
| CN112175003B (zh) * | 2019-07-01 | 2022-02-15 | 上海医药工业研究院 | 一种苯基氢膦酸酯及其中间体的制备方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN112390824B (zh) * | 2019-08-19 | 2022-07-05 | 鲁南制药集团股份有限公司 | 一种替诺福韦艾拉酚胺中间体的制备方法 |
| CN110981911A (zh) * | 2019-10-08 | 2020-04-10 | 浙江车头制药股份有限公司 | 一种替诺福韦艾拉酚胺的制备方法 |
| CN111171076A (zh) * | 2019-12-26 | 2020-05-19 | 合肥启旸生物科技有限公司 | 一种替诺福韦二聚体的制备方法 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| KR20220141457A (ko) | 2021-04-13 | 2022-10-20 | 경동제약 주식회사 | 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물 |
| CR20240223A (es) | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121219281A (zh) | 2023-05-31 | 2025-12-26 | 吉利德科学公司 | 用于治疗hiv的化合物的固体形式 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020119443A1 (en) * | 2000-07-21 | 2002-08-29 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| AU2005330489B2 (en) * | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| HRP20080554B1 (hr) | 2006-03-29 | 2014-11-21 | Gilead Sciences, Inc. | Postupak priprave inhibitora proteaze hiv |
| US20080008682A1 (en) * | 2006-07-07 | 2008-01-10 | Chong Lee S | Modulators of toll-like receptor 7 |
| WO2008011116A2 (en) * | 2006-07-21 | 2008-01-24 | Gilead Sciences, Inc. | Aza-peptide protease inhibitors |
| KR20110089463A (ko) * | 2006-07-24 | 2011-08-08 | 한국화학연구원 | 신규 ｈｉｖ 역전사 효소 억제제 |
| WO2009005693A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| CN107266498B (zh) | 2011-10-07 | 2023-10-03 | 吉利德科学公司 | 制备抗病毒核苷酸类似物的方法 |
-
2012
- 2012-10-03 CN CN201710365515.5A patent/CN107266498B/zh active Active
- 2012-10-03 TW TW108139308A patent/TWI709567B/zh active
- 2012-10-03 UY UY34361A patent/UY34361A/es not_active Application Discontinuation
- 2012-10-03 EP EP18153951.1A patent/EP3333173B1/en active Active
- 2012-10-03 EP EP12798029.0A patent/EP2764002B1/en active Active
- 2012-10-03 PL PL18153951T patent/PL3333173T3/pl unknown
- 2012-10-03 MX MX2014003952A patent/MX353064B/es active IP Right Grant
- 2012-10-03 BR BR112014011340A patent/BR112014011340A2/pt unknown
- 2012-10-03 TW TW106145797A patent/TWI689513B/zh active
- 2012-10-03 PE PE2014000495A patent/PE20141160A1/es not_active Application Discontinuation
- 2012-10-03 KR KR1020147011619A patent/KR102033802B1/ko active Active
- 2012-10-03 AU AU2012319172A patent/AU2012319172B2/en active Active
- 2012-10-03 PT PT18153951T patent/PT3333173T/pt unknown
- 2012-10-03 CA CA3042169A patent/CA3042169C/en active Active
- 2012-10-03 KR KR1020207021316A patent/KR20200090975A/ko not_active Withdrawn
- 2012-10-03 CN CN202110408116.9A patent/CN113264959A/zh active Pending
- 2012-10-03 CA CA2850466A patent/CA2850466C/en active Active
- 2012-10-03 TW TW101136508A patent/TWI557133B/zh active
- 2012-10-03 ES ES18153951T patent/ES2746859T3/es active Active
- 2012-10-03 US US13/573,666 patent/US8664386B2/en active Active
- 2012-10-03 KR KR1020197019875A patent/KR102139440B1/ko active Active
- 2012-10-03 TW TW105126598A patent/TWI613211B/zh active
- 2012-10-03 PT PT127980290T patent/PT2764002T/pt unknown
- 2012-10-03 ES ES12798029.0T patent/ES2661705T3/es active Active
- 2012-10-03 WO PCT/US2012/000441 patent/WO2013052094A2/en not_active Ceased
- 2012-10-03 CN CN202311252160.0A patent/CN117343101A/zh active Pending
- 2012-10-03 SI SI201231626T patent/SI3333173T1/sl unknown
- 2012-10-03 CN CN201280048965.7A patent/CN103842366B/zh active Active
- 2012-10-03 AR ARP120103681 patent/AR088109A1/es not_active Application Discontinuation
- 2012-10-03 EA EA201490753A patent/EA027086B1/ru unknown
- 2012-10-03 JP JP2014534535A patent/JP6190372B2/ja active Active
-
2014
- 2014-01-14 US US14/154,313 patent/US9029534B2/en active Active
- 2014-04-02 IL IL23187914A patent/IL231879B/en active IP Right Grant
- 2014-04-03 CL CL2014000827A patent/CL2014000827A1/es unknown
- 2014-04-11 BR BR102014008928-4A patent/BR102014008928B1/pt active IP Right Grant
- 2014-05-02 CO CO14093468A patent/CO6940431A2/es active IP Right Grant
- 2014-05-05 EC ECIEPI201474A patent/ECSP14000074A/es unknown
- 2014-05-05 CR CR20140204A patent/CR20140204A/es unknown
- 2014-08-21 AU AU2014215976A patent/AU2014215976B2/en active Active
-
2015
- 2015-02-06 HK HK18114351.4A patent/HK1255222B/en unknown
- 2015-04-08 US US14/681,955 patent/US9346841B2/en active Active
-
2016
- 2016-04-21 US US15/135,357 patent/US9676804B2/en active Active
- 2016-09-19 AU AU2016228317A patent/AU2016228317B2/en active Active
-
2017
- 2017-04-19 JP JP2017083047A patent/JP2017160228A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3333173T (pt) | Métodos de preparação de análogos de nucleótidos antivirais | |
| IL274500B1 (en) | glycoconjugation process | |
| EP2828278A4 (en) | PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | |
| IL252345A0 (en) | Antiviral compounds | |
| IL238792A0 (en) | A process for the preparation of nucleoside drug derivatives | |
| IL238578A0 (en) | Spliceostatin analogs | |
| IL239496A0 (en) | Antiviral compounds | |
| SG10201703451RA (en) | Antiviral compounds | |
| ZA201309245B (en) | Novel fluoroergoline analogs | |
| EP2887941A4 (en) | PROCESS FOR THE PREPARATION OF ANTIVIRAL COMPOUNDS | |
| IL238080A0 (en) | Somatostatin-dopamine chimeric analogs | |
| EP2699241A4 (en) | ANTIVIRAL COMPOUNDS | |
| IL228985A0 (en) | Diazonamide analogs | |
| ZA201402374B (en) | Antiviral compounds | |
| GB201222385D0 (en) | Novel compunds |